Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide

Ann Hematol. 2013 Jun;92(6):855-7. doi: 10.1007/s00277-012-1639-3. Epub 2012 Nov 25.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Combined Modality Therapy
  • Dacarbazine / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Epstein-Barr Virus Infections / pathology
  • Epstein-Barr Virus Infections / virology
  • Hematopoietic Stem Cell Transplantation
  • Hodgkin Disease / diagnosis*
  • Hodgkin Disease / pathology
  • Hodgkin Disease / virology
  • Humans
  • Lenalidomide
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / surgery
  • Neoplasms, Second Primary / diagnosis*
  • Neoplasms, Second Primary / pathology
  • Neoplasms, Second Primary / virology
  • Pyrazines / administration & dosage
  • Salvage Therapy
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Transplantation Conditioning / adverse effects
  • Transplantation, Autologous
  • Vinblastine / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Boronic Acids
  • Pyrazines
  • Bleomycin
  • Thalidomide
  • Vincristine
  • Vinblastine
  • Bortezomib
  • Dacarbazine
  • Dexamethasone
  • Doxorubicin
  • Lenalidomide

Supplementary concepts

  • ABVD protocol
  • VAD protocol